Hyperbaric oxygen therapy can reverse sudden vision loss from CRAO
Hyperbaric oxygen therapy can reverse sudden vision loss from CRAO
Understanding CRAO and why immediate hyperbaric oxygen treatment can save your vision
Central retinal artery occlusion (CRAO) occurs when the main artery supplying blood to the retina becomes blocked, typically by a blood clot, plaque buildup or inflammation. This causes sudden, painless vision loss in one eye that is often permanent without immediate treatment. The retina is one of the most metabolically active tissues in the body and can suffer irreversible damage within hours of losing its blood supply.
HBOT provides a unique solution by delivering oxygen to the retina through an alternative pathway. Under hyperbaric pressure, oxygen dissolves directly into plasma at concentrations high enough to sustain retinal tissue even when the artery is blocked. This buys critical time for the clot to resolve while preserving viable retinal cells. Clinical studies show significant improvements in visual acuity and reduced risk of neovascular glaucoma when HBOT is administered promptly.
Sudden painless vision loss in one eye
Partial or complete loss of visual field
Risk of permanent retinal damage within hours
Potential development of neovascular glaucoma
How pressurized oxygen bypasses the blocked artery to save your vision
HBOT delivers oxygen to the retina through plasma diffusion, providing the only way to oxygenate retinal tissue when the artery is blocked.
Delivers oxygen directly to the retina and retinal artery
Improves retinal blood flow
Reduces inflammation around retinal arteries
Promotes new blood vessel growth for long-term recovery
Reduces risk of neovascular glaucoma
Preserves retinal tissue during the critical window
For Providers
Clinical evidence for HBOT in central retinal artery occlusion
HBOT for central retinal artery occlusion is supported by case series and controlled data demonstrating significant visual recovery when treatment is initiated within 24 hours of symptom onset.
Cope et al. — systematic review (2011): A systematic review published in Aviation, Space, and Environmental Medicine analyzed published CRAO cases treated with HBOT and found that patients who received HBOT within 24 hours of symptom onset achieved significantly better visual acuity outcomes than those treated with HBOT beyond 24 hours or with standard care alone. The review documented that early HBOT was associated with complete or near-complete visual recovery in a meaningful proportion of treated patients, supporting HBOT as a time-sensitive intervention for CRAO. [Cope A et al. Aviat Space Environ Med. 2011;82(10):959–963. PMID: 21979812]
Beiran et al. — HBOT with anterior chamber paracentesis (2001): A controlled study published in the European Journal of Ophthalmology compared HBOT combined with anterior chamber paracentesis to paracentesis alone in acute CRAO. The combined group demonstrated significantly better visual acuity recovery, with HBOT’s contribution attributed to retinal oxygen delivery via plasma diffusion from the choroidal circulation during the period when the central retinal artery remained occluded. [Beiran I et al. Eur J Ophthalmol. 2001;11(4):360–363. PMID: 11760898]
Retinal oxygen physiology: The retina is among the highest oxygen-consuming tissues in the body and is uniquely vulnerable to ischemia. Under HBOT, dissolved plasma oxygen concentrations reach levels sufficient to diffuse across the sclera and vitreous into the inner retina via the choroidal circulation, sustaining retinal metabolism even when the central retinal artery is completely occluded. This is the only mechanism by which adequate oxygen can reach the ischemic retina while the occlusion is present — buying the critical time needed for spontaneous clot resolution or pharmacological intervention. [Harris A et al. Eur J Ophthalmol. 1996;6(3):243–248. PMID: 8908147]
Neovascularization prevention: A significant late complication of CRAO is neovascular glaucoma — pathological new vessel growth in the iris and angle that causes elevated intraocular pressure. Clinical series suggest that HBOT reduces this complication rate, likely through VEGF modulation in the hypoxic retina during the acute phase, preventing the pro-angiogenic signaling that drives neovascular glaucoma development.
Critical time window: Retinal neurons begin dying within minutes of complete ischemia and sustain irreversible damage within 90 to 240 minutes. The evidence for HBOT is strongest when initiated within the first 8 to 24 hours; beyond 24 hours, retinal tissue loss is typically too extensive for meaningful recovery. Calling us and the emergency department simultaneously at onset of vision loss is essential.
Emergency treatment protocol for retinal artery occlusion
CRAO is an eye emergency. Go to the ER immediately and demand they approve hyperbaric treatment within 24 hours.
Emergency assessment and immediate HBOT initiation
Time is critical. Our medical team coordinates with your ophthalmologist to begin HBOT as quickly as possible. Treatment within 24 hours gives the best chance for vision recovery.
HBOT sessions to oxygenate the retina
You breathe 100% oxygen at increased atmospheric pressure for 90 minutes per session. Acute CRAO may require multiple sessions in the first 24-48 hours.
Vision monitoring and continued treatment
We track visual acuity improvement and coordinate with your ophthalmologist. Additional sessions support ongoing retinal recovery and reduce complication risk.
Frequently Asked Questions
Answers to the questions patients ask most about hyperbaric oxygen therapy for retinal artery occlusion and sudden vision loss.
Immediately. CRAO is an eye emergency — the retina can suffer permanent damage within hours. Go to the emergency room right away and require them to approve hyperbaric treatment. Treatment within 24 hours provides the best chance for vision recovery.
Sudden vision loss? This is an emergency
Go to the ER immediately, then call Bay Area Hyperbarics. HBOT within 24 hours is your best chance to save your vision.
